Skip to main content
Premium Trial:

Request an Annual Quote

Genomind, Emory Partner to Commercialize Alzheimer's Test

NEW YORK (GenomeWeb News) – Genomind today announced a partnership with Emory University to commercialize a blood-based screening test for mild cognitive impairment and Alzheimer's disease.

Under the terms of the deal, Genomind has attained the exclusive rights to commercialize blood-based protein biomarkers for assessment of the conditions. Other terms of the agreement were not disclosed.

"The development of this test represent one of the most significant efforts to date in making available a simple screening tool for mild cognitive impairment and Alzheimer's disease," Jay Lombard, chief scientific officer and medical director of Genomind, said in a statement. "But even more importantly, this joint effort between Genomind and Emory will allow us to consider preventive approaches for those at highest risk of developing Alzheimer's disease."

According to the Chalfont, Pa.-based company, more than 5 million Americans live with Alzheimer's, which is the sixth leading cause of death in the US.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.